Send a Tweet
Most Popular Choices
Poll Analyses
Share on Facebook 2 Share on Twitter Printer Friendly Page More Sharing
Sci Tech    H4'ed 8/26/16

Brief rapamycin therapy in middle-aged mice extends lives

Follow Me on Twitter     Message Scott Baker
Become a Fan
  (81 fans)
Elife - Transient rapamycin treatment can increase lifespan and healthspan in middle-aged mice.
Elife - Transient rapamycin treatment can increase lifespan and healthspan in middle-aged mice.
(Image by Next Big Future)
  Details   DMCA

In mice, the drug rapamycin is known to extend lives and delay some age-related problems. Questions remain about about how it promotes healthy aging, when, how much and how long to administer rapamycin, and how to avoid serious side effects. A new study showed brief therapy during middle age with rapamycin dramatically extended mouse lives. Findings revealed the need to further examine how gender and dose influence side effects and the drug's impact on susceptibility to and protection from different types of cancer.

Read the rest of the story HERE:

At www.eurekalert.org

 

Well Said 1   News 1   Interesting 1  
Rate It | View Ratings

Scott Baker Social Media Pages: Facebook Page       Twitter Page       Linked In Page       Instagram Page

Scott Baker is a Managing Editor & The Economics Editor at Opednews, and a blogger for Huffington Post, Daily Kos, and Global Economic Intersection.

His anthology of updated Opednews articles "America is Not Broke" was published by Tayen Lane Publishing (March, 2015) and may be found here:
http://www.americaisnotbroke.net/

Scott is a former President of Common Ground-NYC (http://commongroundnyc.org/), a Geoist/Georgist activist group. He has written dozens of articles for (more...)
 

Go To Commenting
The views expressed herein are the sole responsibility of the author and do not necessarily reflect those of this website or its editors.
Follow Me on Twitter     Writers Guidelines
Contact AuthorContact Author Contact EditorContact Editor Author PageView Authors' Articles
Support OpEdNews

OpEdNews depends upon can't survive without your help.

If you value this article and the work of OpEdNews, please either Donate or Purchase a premium membership.

STAY IN THE KNOW
If you've enjoyed this, sign up for our daily or weekly newsletter to get lots of great progressive content.
Daily Weekly     OpEdNews Newsletter
Name
Email
   (Opens new browser window)
 

To View Comments or Join the Conversation: